Journal of Thermal Analysis and Calorimetry

, Volume 127, Issue 1, pp 535–542 | Cite as

Solid-state characterization and pharmaceutical compatibility between citalopram and excipients using thermal and non-thermal techniques

  • S. A. Pires
  • W. N. Mussel
  • M. I. Yoshida


Differential scanning calorimetry (DSC) has been used in combination with powder X-ray diffraction (PXRD) and solid-state nuclear magnetic resonance (SSNMR) for evaluation of drug–excipient interaction. This study aimed to evaluate the antidepressive citalopram hydrobromide and the most usual excipient commonly used for the evaluation of their compatibility in binary mixtures. The TG/DTG curves reveal that citalopram is thermally stable up to 230 °C, presenting a sharp endothermic peak at 183 °C (T onset = 185 °C) that corresponds to its melting point. Only for citalopram–lactose binary mixture was observed dislocation of the melting event in the DSC curves; however, this change has not indicated to be an interaction between the components in this case, but an overlap of events of lactose and citalopram. PXRD pattern suggests that no interaction is present between individual components that still showing the same crystalline structure for citalopram. The SSNMR spectrum assignment was done based on computational prediction of chemical shifts comparing it with its original spectrum. The chemical shifts confirmed the expected structure. Therefore, since changes in chemical shift are smaller than 1 ppm, no evidence of chemical interaction between the components of each binary mixture was confirmed.


Citalopram Compatibility studies Thermal analysis PXRD SSNMR 



The authors are grateful to CNPq, CAPES, and FAPEMIG for the financial support.


  1. 1.
    Oruch R, Hodneland E, Pryme IE, Holmsen H. In thrombin stimulated human platelets citalopram, promethazine, risperidone, and ziprasidone, but not diazepam, may exert their pharmacological effects also through intercalation in membrane phospholipids in a receptor-independent manner. J Chem Biol. 2009;2:89–103.CrossRefGoogle Scholar
  2. 2.
    Bertol CD, Cruz AP, Stulzer HK, Murakami FS, Silva MAS. Thermal decomposition kinetics and compatibility studies of primaquine under isothermal and non-isothermal conditions. J Therm Anal Calorim. 2010;102:187–92.CrossRefGoogle Scholar
  3. 3.
    Abdellah A, Noordin MI, Wan Ismail WA. Importance and globalization status of good manufacturing practice (GMP) requirements for pharmaceutical excipients. Saudi Pharm J. 2015;23:9–13.CrossRefGoogle Scholar
  4. 4.
    Tita B, Fulias A, Bandur G, Marian E, Tita D. Compatibility study between ketoprofen and pharmaceutical excipients used in solid dosage forms. J Pharm Biomed Anal. 2011;56:221–7.CrossRefGoogle Scholar
  5. 5.
    ICH Stability testing of new drug substances and products. In: Proceedings of the international conference on Harmonization. Geneva: IFPMA; 2003.Google Scholar
  6. 6.
    Shantikumar S, Sreekanth G, SurendraNath KV, JaferValli S, Satheeshkumar N. Compatibility study between sitagliptin and pharmaceutical excipients used in solid dosage forms. J Therm Anal Calorim. 2014;115:2423–8.CrossRefGoogle Scholar
  7. 7.
    Wang Y, Luo Y-H, Zhao J, Sun B-H. Selection of excipients for dispersible tablets of itraconazole through the application of thermal techniques and Raman spectroscopy. J Therm Anal Calorim. 2014;115:2391–400.CrossRefGoogle Scholar
  8. 8.
    Chadha R, Bhandari S. Drug–excipient compatibility screening: role of thermoanalytical and spectroscopic techniques. J Pharm Biomed Anal. 2014;87:82–97.CrossRefGoogle Scholar
  9. 9.
    Skotnicki M, Aguilar JA, Pyda M, Hodgkinson P. Bisoprolol and bisoprolol–valsartan compatibility studied by differential scanning calorimetry, nuclear magnetic resonance and X-ray powder diffractometry. Pharm Res. 2015;32:414–29.CrossRefGoogle Scholar
  10. 10.
    Byrn SR, Xu W, Newman AW. Chemical reactivity in solid-state pharmaceuticals: formulation implications. Adv Drug Deliv Rev. 2001;48:115–36.CrossRefGoogle Scholar
  11. 11.
    Holzgrabe U, Diehl B, Wawer I. NMR spectroscopy in pharmaceutical analysis. Amsterdam: Elsevier; 2008.Google Scholar
  12. 12.
    Gao R, Jin Y, Yang Q-Y, Sun B-W, Lin J. Study of stability and drug–excipient compatibility of estradiol and pharmaceutical excipients. J Therm Anal Calorim. 2015;120:839–45.CrossRefGoogle Scholar
  13. 13.
    Chaves LL, Rolim LA, Gonçalves Maria LCM, Vieira ACC, Alves LDS, Soares MFR, Soares-Sobrinho JL, Lima MCA, Rolim-Neto PJ. Study of stability and drug–excipient compatibility of diethylcarbamazine citrate. J Therm Anal Calorim. 2013;111:2179–86.CrossRefGoogle Scholar
  14. 14.
    Abbas D, Orneto JKC, Piccerelle P, Portugal H, Nicolay A. DSC and physico-chemical properties of a substituted pyridoquinoline and its interaction study with excipients. J Therm Anal Calorim. 2008;93:353–60.CrossRefGoogle Scholar
  15. 15.
    Pisklak DM, Zielinska-Pisklak MA, Szeleszcsuk L, Wawer I. 13C solid-state NMR analysis of the most common pharmaceutical excipients used in solid drug formulations, Part I: chemical shifts assignment. J Pharm Biomed Anal. 2016;122:81–9.CrossRefGoogle Scholar
  16. 16.
    Yasmeen BR, Firoz S, Mouli YC, Vikram A, Mahitha B, Aruna U. Preparation and evaluation of oral fast dissolving films of citalopram hydrobromide. Int J Biopharma. 2012;3:103–6.Google Scholar
  17. 17.
    The (USP) Convention. United States Pharmacopeia. 34th ed. Rockville; 2011.Google Scholar
  18. 18.
    Pereira MAV, Fonseca GD, Silva-Júnior AA, Fernandes-Pedrosa MF, de Moura FV, Barbosa EG, Gomes APB, dos Santos KSCR. Compatibility study between chitosan and pharmaceutical excipients used in solid dosage forms. J Therm Anal Calorim. 2014;116:1091–100.CrossRefGoogle Scholar
  19. 19.
    Raman B, Sharma BA, Ghugare PD, Karmuse PP, Kumar A. Semi-preparative isolation and structural elucidation of an impurity in citalopram by LC/MS/MS. J Pharm Biomed Anal. 2009;50:377–83.CrossRefGoogle Scholar
  20. 20.
    Thomas S, Agarwal A, Rao RD, Mathela CS. Characterization of an unknown impurity in citalopram hydrobromide active pharmaceutical ingredient by semi-preparative isolation and LC-ESI/MSn and NMR. J Liq Chromatogr Relat Technol. 2013;36:1999–2002.Google Scholar
  21. 21.
    Geppi M, Mollica G, Borsacchi S, Veracini CA. Solid-state NMR studies of pharmaceutical systems. Appl Spectrosc Rev. 2008;43:202–302.CrossRefGoogle Scholar

Copyright information

© Akadémiai Kiadó, Budapest, Hungary 2016

Authors and Affiliations

  1. 1.Departamento de QuímicaUniversidade Federal de Minas GeraisBelo HorizonteBrazil

Personalised recommendations